X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs BIOCON LTD - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA BIOCON LTD SUN PHARMA/
BIOCON LTD
 
P/E (TTM) x 15.8 36.6 43.2% View Chart
P/BV x 3.7 4.9 76.4% View Chart
Dividend Yield % 0.2 1.5 13.6%  

Financials

 SUN PHARMA   BIOCON LTD
EQUITY SHARE DATA
    SUN PHARMA
Mar-16
BIOCON LTD
Mar-16
SUN PHARMA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1,201496 242.2%   
Low Rs706397 178.2%   
Sales per share (Unadj.) Rs117.5174.3 67.4%  
Earnings per share (Unadj.) Rs19.644.8 43.7%  
Cash flow per share (Unadj.) Rs23.856.9 41.8%  
Dividends per share (Unadj.) Rs1.005.00 20.0%  
Dividend yield (eoy) %0.11.1 9.4%  
Book value per share (Unadj.) Rs130.5202.8 64.4%  
Shares outstanding (eoy) m2,406.60200.00 1,203.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x8.12.6 317.1%   
Avg P/E ratio x48.710.0 488.7%  
P/CF ratio (eoy) x40.17.8 511.1%  
Price / Book Value ratio x7.32.2 332.2%  
Dividend payout %5.111.2 45.7%   
Avg Mkt Cap Rs m2,294,81389,220 2,572.1%   
No. of employees `00014.74.4 334.0%   
Total wages/salary Rs m47,9716,363 753.9%   
Avg. sales/employee Rs Th19,169.87,894.5 242.8%   
Avg. wages/employee Rs Th3,253.01,441.2 225.7%   
Avg. net profit/employee Rs Th3,197.92,029.7 157.6%   
INCOME DATA
Net Sales Rs m282,69734,854 811.1%  
Other income Rs m6,170845 730.1%   
Total revenues Rs m288,86735,699 809.2%   
Gross profit Rs m83,2398,200 1,015.1%  
Depreciation Rs m10,1352,423 418.3%   
Interest Rs m4,769102 4,675.4%   
Profit before tax Rs m74,5056,520 1,142.7%   
Minority Interest Rs m-11,126-744 1,495.4%   
Prior Period Items Rs m-190-   
Extraordinary Inc (Exp) Rs m-6,8525,754 -119.1%   
Tax Rs m9,3492,569 363.9%   
Profit after tax Rs m47,1598,961 526.3%  
Gross profit margin %29.423.5 125.2%  
Effective tax rate %12.539.4 31.8%   
Net profit margin %16.725.7 64.9%  
BALANCE SHEET DATA
Current assets Rs m308,64639,932 772.9%   
Current liabilities Rs m132,47716,276 813.9%   
Net working cap to sales %62.367.9 91.8%  
Current ratio x2.32.5 95.0%  
Inventory Days Days8354 154.9%  
Debtors Days Days8886 101.8%  
Net fixed assets Rs m133,60639,101 341.7%   
Share capital Rs m2,4071,000 240.7%   
"Free" reserves Rs m266,90938,591 691.6%   
Net worth Rs m314,04240,556 774.3%   
Long term debt Rs m31,16720,724 150.4%   
Total assets Rs m542,19684,816 639.3%  
Interest coverage x16.664.9 25.6%   
Debt to equity ratio x0.10.5 19.4%  
Sales to assets ratio x0.50.4 126.9%   
Return on assets %9.610.7 89.6%  
Return on equity %15.022.1 68.0%  
Return on capital %17.819.0 93.5%  
Exports to sales %14.030.7 45.5%   
Imports to sales %3.120.4 15.4%   
Exports (fob) Rs m39,57210,717 369.2%   
Imports (cif) Rs m8,8827,105 125.0%   
Fx inflow Rs m42,17111,789 357.7%   
Fx outflow Rs m21,5838,393 257.2%   
Net fx Rs m20,5883,396 606.3%   
CASH FLOW
From Operations Rs m67,6945,264 1,286.0%  
From Investments Rs m-44,549-9,540 467.0%  
From Financial Activity Rs m-19,24310,867 -177.1%  
Net Cashflow Rs m3,9026,591 59.2%  

Share Holding

Indian Promoters % 63.7 40.4 157.7%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 5.1 8.4 61.1%  
FIIs % 23.0 10.7 215.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 19.9 41.7%  
Shareholders   133,026 109,995 120.9%  
Pledged promoter(s) holding % 0.5 0.0 1,325.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  FDC LTD.  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare SUN PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Tata Global Beverages Surges 8.3%(Closing)

Indian share markets snapped their losing streak of last week and finished the trading day on a strong note due to strong buying momentum in FMCG stocks, metal stocks and auto stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Aug 16, 2017 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS